Not Yet Recruiting NA INTERVENTIONAL 1-arm NCT07281664

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

Conditions Hepatocellular Carcinoma Transarterial Chemoembolization

Interventions Transarterial chemoembolization (TACE) bevacizumab and atezolizumab

Updated 1 time since 2026 Last updated: Dec 12, 2025 Started: Jan 1, 2026 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hepatocellular Carcinoma and Transarterial Chemoembolization, this trial is actively recruiting participants. The trial is conducted by Third Affiliated Hospital, Sun Yat-Sen University and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — NA [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Third Affiliated Hospital, Sun Yat-Sen University

Data source: Third Affiliated Hospital, Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.